Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Ning Ning

Interventional Cardiology Burlingame, CA Medical Doctor

NPI 1356704662 CMS profile 11430857

1501 Trousdale Dr, Fl 2, Burlingame, CA 94010

Open in the dashboard

General payments

$123,610

111 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ning Ning of Burlingame, CA is reported in the CMS Open Payments database as having received $123,610 across 111 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,076 11
2024 General $3,576 49
2023 General $114,690 35
2022 General $4,268 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ning Ning
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Ning Ning were reported at $1,076. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Ning Ning Interventional Cardiology median Middle half National median
2019 $0 $1,097 $329–$3,048 $163
2020 $0 $473 $161–$1,480 $114
2021 $0 $677 $233–$1,827 $132
2022 $4,268 $978 $333–$2,724 $149
2023 $114,690 $1,136 $382–$2,986 $160
2024 $3,576 $1,181 $395–$3,326 $164
2025 $1,076 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Boston Scientific Corporation $87,721 47 payments
  2. Abbott Laboratories $23,577 22 payments
  3. Medtronic, Inc. $8,955 10 payments
  4. Shockwave Medical, Inc $1,278 8 payments
  5. Penumbra, Inc. $1,031 10 payments
  6. Abiomed $359 3 payments
  7. Philips Electronics North America Corporation $160 4 payments
  8. Cardiovascular Systems Inc. $148 1 payment
  9. Biotronik Inc. $115 1 payment
  10. Cardiva Medical, Inc. $112 1 payment
  11. Other $154 4 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Grant $110,500 4 payments
  2. Food and Beverage $6,903 83 payments
  3. Travel and Lodging $6,206 24 payments
Products named General payments · program years 2022–2025
  1. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $1,278 8 payments
  2. SYMPLICITY G3 $955 9 payments
  3. Indigo System $941 8 payments
  4. OPTIS $832 17 payments
  5. AngioJet Ultra 5000A $358 2 payments
  6. Impella $283 2 payments
  7. Ranger $226 5 payments
  8. Diamondback Coronary Vascular $166 1 payment
  9. (BQ9) Coronary IVUS $160 4 payments
  10. Diamondback Coronary Atherectomy Device $148 1 payment
  11. Other $851 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

86

Median for Cardiology: 2,533

Drug cost

$18,492

Median for Cardiology: $485,213

Branded share of claims

68.6%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 11 $11,621
Brilinta Ticagrelor Brand 12 $6,054
Clopidogrel Clopidogrel Bisulfate Brand 36 $571
Atorvastatin Calcium Generic 27 $245

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$50,890

Medicare's payments for the services billed

Medicare patients

124

Average age 77

Services billed

389

53 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 71%
Atrial fibrillation 54%
Chronic kidney disease 52%
Diabetes 50%
Arthritis 45%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

111 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record